1. Home
  2. Analysis
  3. Urso-250
  4. Novantrone

Urso 250 and Novantrone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Urso 250 and Novantrone. Common interactions include brain stem haemorrhage among females and anaemia among males.

The phase IV clinical study analyzes what interactions people who take Urso 250 and Novantrone have. It is created by eHealthMe based on reports of 6 people who take Urso 250 and Novantrone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 08, 2023

6 people who take Urso 250 and Novantrone together, and have interactions are studied.

What is Urso 250?

Urso 250 has active ingredients of ursodiol. eHealthMe is studying from 5,068 Urso 250 users for its effectiveness, alternative drugs and more.

What is Novantrone?

Novantrone has active ingredients of mitoxantrone hydrochloride. It is often used in multiple sclerosis. eHealthMe is studying from 3,310 Novantrone users for its effectiveness, alternative drugs and more.

Number of Urso 250 and Novantrone reports submitted per year:

Urso 250 and Novantrone drug interactions.

Common Urso 250 and Novantrone drug interactions by gender *:

female:

  1. Brain stem haemorrhage
  2. Cerebral haemorrhage
  3. Cytomegalovirus viraemia
  4. Hyperuricaemia
  5. Renal impairment

male:

  1. Anaemia
  2. Central line infection
  3. White blood cell count decreased
  4. Febrile neutropenia
  5. Fibrin degradation products increased
  6. Pancytopenia
  7. Pseudomembranous colitis
  8. Pseudomonal sepsis
  9. Sepsis
  10. Sudden death

Common Urso 250 and Novantrone drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Cytomegalovirus viraemia
  2. Hyperuricaemia
  3. Renal impairment

30-39:

  1. Brain stem haemorrhage
  2. Cerebral haemorrhage

40-49:

n/a

50-59:

  1. Anaemia
  2. Central line infection
  3. Fibrin degradation products increased
  4. Sepsis
  5. Venoocclusive liver disease
  6. White blood cell count decreased

60+:

  1. Pseudomonal sepsis
  2. Sudden death

* Approximation only. Some reports may have incomplete information.

Do you take Urso 250 and Novantrone?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Urso 250 and Novantrone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Urso 250 side effects:

Browse all side effects of Urso 250:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Novantrone side effects:

Browse all side effects of Novantrone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Urso 250 interactions:

Browse all interactions between Urso 250 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Novantrone interactions:

Browse all interactions between Novantrone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ursodiol and mitoxantrone hydrochloride (the active ingredients of Urso 250 and Novantrone, respectively), and Urso 250 and Novantrone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Urso 250 and Novantrone.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.